Novel mechanism of lapatinib resistance in HER2-positive breast tumor cells: activation of AXL.

@article{Liu2009NovelMO,
  title={Novel mechanism of lapatinib resistance in HER2-positive breast tumor cells: activation of AXL.},
  author={Li Liu and James Greger and Hong Fei Shi and Yuan Liu and Joel Greshock and Roland S. Annan and Wendy S. Halsey and Ganesh M. Sathe and A M Martin and Tona M. Gilmer},
  journal={Cancer research},
  year={2009},
  volume={69 17},
  pages={6871-8}
}
HER2-directed therapies, such as trastuzumab and lapatinib, are important treatments for breast cancer. However, some tumors do not respond or develop resistance to these agents. We isolated and characterized multiple lapatinib-resistant, HER2-positive, estrogen receptor (ER)-positive breast cancer clones derived from lapatinib-sensitive BT474 cells by chronic exposure to lapatinib. We show overexpression of AXL as a novel mechanism of acquired resistance to HER2-targeted agents in these models… CONTINUE READING
Highly Influential
This paper has highly influenced a number of papers. REVIEW HIGHLY INFLUENTIAL CITATIONS